Varenicline for Smoking Cessation in Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Study
The DOI matches its Crossref record, with a small difference in title or year.
Abstract
OBJECTIVE: Virtually no clinical trials for smoking cessation have been undertaken in bipolar disorder. Varenicline has shown efficacy for smoking cessation, but warnings about neuropsychiatric adverse events have been issued. We assessed the efficacy and safety of varenicline in euthymic bipolar subjects motivated to quit smoking. METHOD: Clinically stable adult patients with DSM-IV bipolar disorder (n = 60) who smoked ≥ 10 cigarettes per day were randomized to a 3-month, double-blind, placebo-controlled varenicline trial and a 3-month follow-up. Study enrollment was completed from February 2010 through March 2013. Varenicline was dosed using standard titration, and smoking cessation counseling was provided to all patients. The primary outcome was defined as a 7-day point prevalence of self-reported no smoking verified by expired carbon monoxide level < 10 ppm at 12 weeks. Psychopathology and side-effects were assessed at each visit. RESULTS: At 3 months (end of treatment), significantly more subjects quit smoking with varenicline (n/n = 15/31, 48.4%) than with placebo (n/n = 3/29, 10.3%) (OR = 8.1; 95% CI, 2.03-32.5; P < .002). At 6 months, 6 of 31 varenicline-treated subjects (19.4%) remained abstinent compared to 2 of 29 (6.90%) assigned to placebo (OR = 3.2; 95% CI, 0.60-17.6; P = .17). Psychopathology scores remained stable. Ten serious adverse events occurred (n = 6, varenicline; n = 4, placebo). Abnormal dreams occurred significantly more often in varenicline-treated subjects (n/n = 18/31, 61.3%) than in those receiving placebo (n/n = 9/29, 31%; Fisher exact test, P = .04). Eight varenicline-treated and 5 placebo-assigned subjects expressed fleeting suicidal ideation, a nonsignificant difference. CONCLUSIONS: Varenicline shows efficacy for initiating smoking cessation in bipolar patients, but medication trials of longer duration are warranted for maintaining abstinence. Vigilance for neuropsychiatric adverse events is prudent when initiating varenicline for smoking cessation in this patient population. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01010204.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Six of eight published studies focused on smoking cessation for people with BD have sample sizes of twenty or less”
From Smokers with bipolar disorder, other affective disorders, and no mental health conditions: Comparison of baseline characteristics and success at quitting in a large 12-month behavioral intervention randomized trial. (2018) · cites this paper as Chengappa et al., 2014
In the citing paper
“All studies were in favor of the specific treatment.”
From The detrimental effects of smoking on the course and outcome in adults with bipolar disorder—A narrative review (2023) · cites this paper as [73]
In the citing paper
“We identified only four published smoking cessation treatment trials in smokers with BD: one very small open pilot study with bupropion (70), two open pilot studies with varenicline (71, 72), and 2 studies using varenicline either alone (73) or in combination with CBT (74).”
From The detrimental effects of smoking on the course and outcome in adults with bipolar disorder—A narrative review (2023) · cites this paper as [73]
Citations
Cites
Still being checked.
Cited by
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“A variety of strategies may be employed including supportive programmes (telephone, group), nicotine supplements and varenicline (Chengappa et al., 2014; Evins et al., 2014).”
BackgroundNicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub7 · Cited by 433
Smoking cessation for improving mental health
Taylor, G. M., Lindson, N., Farley, A., Leinberger-Jabari, A., Sawyer, K., te Water Naudé, R., Theodoulou, A., King, N., Burke, C., & Aveyard, P. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013522.pub2 · Cited by 266
Cigarette Smoking by Patients With Serious Mental Illness, 1999–2016: An Increasing Disparity
Dickerson, F., Schroeder, J., Katsafanas, E., Khushalani, S., Origoni, A. E., Savage, C., Schweinfurth, L., Stallings, C. R., Sweeney, K., & Yolken, R. H. (2018) · Psychiatric Services · doi:10.1176/appi.ps.201700118 · Cited by 190
Metadata
- Authors
- Chengappa, K. N. R., Perkins, K. A., Brar, J. S., Schlicht, P. J., Turkin, S. R., Hetrick, M. L., Levine, M. D., & George, T. P.
- Affiliations
- University of Pittsburgh Medical Center (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2014-06-10
- Volume
- 75
- Issue
- 07
- Pages
- 765-772
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2089345569
- Cited by
- 86
- References
- 0
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 1 · 2023: 11 · 2022: 4 · 2021: 9 · 2020: 5 · 2019: 7 · 2018: 7 · 2017: 9 · 2016: 9 · 2015: 18 · 2014: 1
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (R21MH087928)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- varenicline, smoking cessation, bipolar disorder, nicotine dependence, neuropsychiatric adverse effects, suicidal ideation, smoking abstinence, smoking cessation counseling, expired carbon monoxide, mood stabilizers
- MeSH terms
- Varenicline, Adult, Benzazepines, Bipolar Disorder, Double-Blind Method, Female, Humans, Male, Middle Aged, Quinoxalines, Smoking, Comorbidity, Smoking Cessation, Treatment Outcome, Nicotinic Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Varenicline for Smoking Cessation in Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Study. https://app.cochat.ai/papers/10.4088/jcp.13m08756
- The paper
- Chengappa, K. N. R., Perkins, K. A., Brar, J. S., Schlicht, P. J., Turkin, S. R., Hetrick, M. L., Levine, M. D., & George, T. P. (2014). Varenicline for Smoking Cessation in Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Study. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.13m08756
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.